Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
National Institutes of Health
Free. Verify your email, then we send one reminder only.
- Posted
- Dec 17, 2025
- Closes
- Jun 2, 2027 (in 276 days)
Similar opportunities open now
- Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jun 2027
- NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses in 75 daysUp to $350K
- Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Jun 2028
- NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses in 75 daysUp to $1.1M
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses in 79 days
Classification and identifiers
- Solicitation number
- PAR-25-211
- Assistance listing (CFDA)
- 93.393
Amount
Amount not published by the funder
Who can apply
Nonprofits, including small and volunteer-run organizations, Local government agencies, and Public colleges and universities can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as ...
About this opportunity
The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions using a milestone-driven, biphasic award mechanism, R61/R33 Phased Innovation Award. Specifically, this NOFO solicits applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. The first phase, funded by the R61, will providing for up to 2 years to identify unique host biological patterns (e.g....